Symbols / PYXS Stock $1.88 +9.94% Pyxis Oncology, Inc.

Healthcare • Biotechnology • United States • NMS
PYXS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Stock Fundamentals
Scroll to Statements
Market Cap 118.12M Enterprise Value 69.94M Income -79.62M Sales 13.86M Book/sh 0.85 Cash/sh 1.06
Dividend Yield — Payout 0.00% Employees 56 IPO — P/E — Forward P/E -1.44
PEG — P/S 8.52 P/B 2.21 P/C — EV/EBITDA -0.90 EV/Sales 5.05
Quick Ratio 3.20 Current Ratio 3.41 Debt/Eq 34.96 LT Debt/Eq — EPS (ttm) -1.28 EPS next Y -1.30
EPS Growth — Revenue Growth — Earnings 2026-05-14 ROA -41.14% ROE -91.44% ROIC —
Gross Margin 82.77% Oper. Margin -159.48% Profit Margin 0.00% Shs Outstand 62.83M Shs Float 40.40M Short Float 5.11%
Short Ratio 7.69 Short Interest — 52W High 5.55 52W Low 0.97 Beta 1.42 Avg Volume 401.48K
Volume 662.87K Target Price $6.88 Recom Strong_buy Prev Close $1.71 Price $1.88 Change 9.94%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.88
Mean price target
2. Current target
$1.88
Latest analyst target
3. DCF / Fair value
$-8.99
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.88
Low
$5.00
High
$9.00
Mean
$6.88

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-24 main Stifel Buy → Buy $8
2026-03-24 reit HC Wainwright & Co. Buy → Buy $7
2025-12-19 main RBC Capital Outperform → Outperform $5
2025-12-19 main HC Wainwright & Co. Buy → Buy $7
2025-11-24 main Stephens & Co. Overweight → Overweight $8
2025-11-04 main Guggenheim Buy → Buy $7
2025-09-04 init Guggenheim — → Buy $5
2025-08-19 reit HC Wainwright & Co. Buy → Buy $5
2025-05-19 reit HC Wainwright & Co. Buy → Buy $5
2025-03-19 reit RBC Capital Outperform → Outperform $8
2025-03-19 reit HC Wainwright & Co. Buy → Buy $5
2024-12-20 reit HC Wainwright & Co. Buy → Buy $5
2024-12-20 reit RBC Capital Outperform → Outperform $8
2024-11-21 main RBC Capital Outperform → Outperform $10
2024-11-21 down William Blair Outperform → Market Perform —
2024-11-21 reit HC Wainwright & Co. Buy → Buy $7
2024-11-08 init Stephens & Co. — → Overweight $13
2024-09-19 reit RBC Capital Outperform → Outperform $7
2024-08-16 reit HC Wainwright & Co. Buy → Buy $7
2024-08-08 init Stifel — → Buy $10
News
RSS: Latest PYXS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-24 WADHANE JITENDRA Chief Financial Officer — 109,461 $0.00 $0
2025-04-21 HUMPHREY RACHEL W M.D. Director — 15,496 $0.97 $15,917
2024-11-26 CONNEALY PAMELA ANN Chief Operating Officer — 88,850 $1.96 $174,364
2024-06-07 PALANI SANTHOSH Director — 6,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
13.86
-14.17%
16.15
0.00
0.00
Operating Revenue
13.86
-14.17%
16.15
0.00
0.00
Cost Of Revenue
2.39
+402.74%
0.47
0.00
—
Reconciled Cost Of Revenue
2.39
+402.74%
0.47
0.00
—
Gross Profit
11.47
-26.81%
15.67
0.00
—
Operating Expense
95.89
+13.93%
84.17
+2.40%
82.20
-33.43%
123.48
Research And Development
73.70
+25.45%
58.75
+18.47%
49.59
-42.43%
86.13
Selling General And Administration
22.19
-12.69%
25.42
-22.05%
32.61
-12.70%
37.35
General And Administrative Expense
22.19
-12.69%
25.42
-22.05%
32.61
-12.70%
37.35
Salaries And Wages
13.88
-12.04%
15.78
-25.18%
21.09
+12.59%
18.73
Other Gand A
4.18
-6.95%
4.49
-29.24%
6.35
-51.40%
13.06
Total Expenses
98.28
+16.11%
84.64
+2.98%
82.20
-33.43%
123.48
Operating Income
-84.42
-23.25%
-68.50
+16.67%
-82.20
+33.43%
-123.48
Total Operating Income As Reported
-84.42
+5.63%
-89.46
-8.84%
-82.20
+33.43%
-123.48
EBITDA
-79.91
-21.97%
-65.51
+18.38%
-80.27
+34.62%
-122.77
Normalized EBITDA
-79.91
-79.37%
-44.55
+44.50%
-80.27
+34.62%
-122.77
Reconciled Depreciation
4.51
+51.27%
2.98
+54.75%
1.93
+171.79%
0.71
EBIT
-84.42
-23.25%
-68.50
+16.67%
-82.20
+33.43%
-123.48
Total Unusual Items
0.00
+100.00%
-20.96
0.00
—
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-20.96
0.00
—
Special Income Charges
0.00
+100.00%
-20.96
0.00
—
Impairment Of Capital Assets
0.00
-100.00%
20.96
0.00
—
Net Income
-79.62
-2.96%
-77.33
-4.80%
-73.79
+38.87%
-120.72
Pretax Income
-78.23
+1.59%
-79.50
-7.73%
-73.79
+38.87%
-120.72
Net Non Operating Interest Income Expense
3.61
-48.71%
7.04
+6.17%
6.63
+139.87%
2.76
Net Interest Income
3.61
-48.71%
7.04
+6.17%
6.63
+139.87%
2.76
Interest Income Non Operating
3.61
-48.71%
7.04
+6.17%
6.63
+139.87%
2.76
Interest Income
3.61
-48.71%
7.04
+6.17%
6.63
+139.87%
2.76
Other Income Expense
2.58
+114.28%
-18.04
-1115.65%
1.78
—
Other Non Operating Income Expenses
2.58
-12.00%
2.93
+64.75%
1.78
—
Gain On Sale Of Security
—
—
—
—
Tax Provision
1.39
+164.05%
-2.16
0.00
—
Tax Rate For Calcs
0.00
+707.69%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.55
0.00
0.00
Net Income Including Noncontrolling Interests
-79.62
-2.96%
-77.33
-4.80%
-73.79
+38.87%
-120.72
Net Income From Continuing Operation Net Minority Interest
-79.62
-2.96%
-77.33
-4.80%
-73.79
+38.87%
-120.72
Net Income From Continuing And Discontinued Operation
-79.62
-2.96%
-77.33
-4.80%
-73.79
+38.87%
-120.72
Net Income Continuous Operations
-79.62
-2.96%
-77.33
-4.80%
-73.79
+38.87%
-120.72
Normalized Income
-79.62
-39.90%
-56.91
+22.87%
-73.79
+38.87%
-120.72
Net Income Common Stockholders
-79.62
-2.96%
-77.33
-4.80%
-73.79
+38.87%
-120.72
Diluted EPS
—
-1.32
+28.65%
-1.85
+49.32%
-3.65
Basic EPS
—
-1.32
+28.65%
-1.85
+49.32%
-3.65
Basic Average Shares
—
58.45
+46.46%
39.90
+20.80%
33.03
Diluted Average Shares
—
58.45
+46.46%
39.90
+20.80%
33.03
Diluted NI Availto Com Stockholders
-79.62
-2.96%
-77.33
-4.80%
-73.79
+38.87%
-120.72
Earnings From Equity Interest
—
—
—
0.00
Insurance And Claims
4.13
-19.69%
5.15
-0.46%
5.17
-6.94%
5.56
Line Item Trend 2023-12-31
Total Assets
173.73
Current Assets
124.60
Cash Cash Equivalents And Short Term Investments
119.30
Cash And Cash Equivalents
9.66
Other Short Term Investments
109.63
Receivables
0.02
Other Receivables
—
Accrued Interest Receivable
0.02
Prepaid Assets
1.01
Restricted Cash
1.47
Other Current Assets
2.82
Total Non Current Assets
49.12
Net PPE
24.81
Gross PPE
28.42
Accumulated Depreciation
-3.60
Properties
0.00
Machinery Furniture Equipment
1.12
Construction In Progress
0.00
Other Properties
16.34
Leases
10.96
Goodwill And Other Intangible Assets
24.31
Other Intangible Assets
24.31
Other Non Current Assets
—
Total Liabilities Net Minority Interest
48.02
Current Liabilities
25.76
Payables And Accrued Expenses
11.29
Payables
3.90
Accounts Payable
3.90
Current Accrued Expenses
7.40
Pensionand Other Post Retirement Benefit Plans Current
5.22
Current Debt And Capital Lease Obligation
1.23
Current Capital Lease Obligation
1.23
Current Deferred Liabilities
7.66
Current Deferred Revenue
7.66
Other Current Liabilities
0.36
Total Non Current Liabilities Net Minority Interest
22.26
Long Term Debt And Capital Lease Obligation
20.10
Long Term Capital Lease Obligation
20.10
Non Current Deferred Liabilities
2.16
Non Current Deferred Taxes Liabilities
2.16
Stockholders Equity
125.70
Common Stock Equity
125.70
Capital Stock
0.04
Common Stock
0.04
Preferred Stock
0.00
Share Issued
44.75
Ordinary Shares Number
44.75
Treasury Shares Number
0.00
Additional Paid In Capital
411.82
Retained Earnings
-286.23
Gains Losses Not Affecting Retained Earnings
0.06
Other Equity Adjustments
0.06
Total Equity Gross Minority Interest
125.70
Total Capitalization
125.70
Working Capital
98.84
Invested Capital
125.70
Total Debt
21.33
Capital Lease Obligations
21.33
Net Tangible Assets
101.40
Tangible Book Value
101.40
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-63.50
-10.11%
-57.67
+18.44%
-70.71
+20.85%
-89.33
Cash Flow From Continuing Operating Activities
-63.50
-10.11%
-57.67
+18.44%
-70.71
+20.85%
-89.33
Net Income From Continuing Operations
-79.62
-2.96%
-77.33
-4.80%
-73.79
+38.87%
-120.72
Depreciation Amortization Depletion
4.51
+51.27%
2.98
+54.75%
1.93
+171.79%
0.71
Depreciation And Amortization
4.51
+51.27%
2.98
+54.75%
1.93
+171.79%
0.71
Other Non Cash Items
0.82
+17.71%
0.70
+6.06%
0.66
-93.66%
10.41
Stock Based Compensation
11.80
-8.84%
12.95
-23.61%
16.95
+7.50%
15.76
Asset Impairment Charge
0.00
-100.00%
20.96
0.00
—
Operating Gains Losses
—
—
—
—
Gain Loss On Investment Securities
—
—
—
—
Change In Working Capital
1.94
+116.43%
-11.82
-1.36%
-11.66
-359.14%
4.50
Change In Prepaid Assets
0.26
+228.57%
-0.20
-108.02%
2.53
+174.89%
-3.38
Change In Payables And Accrued Expense
3.20
+781.49%
-0.47
+97.33%
-17.60
-585.90%
3.62
Change In Accrued Expense
-2.82
-69.04%
-1.67
+88.15%
-14.10
-217.96%
11.95
Change In Payable
6.03
+402.17%
1.20
+134.22%
-3.51
+57.89%
-8.33
Change In Account Payable
6.03
+402.17%
1.20
+134.22%
-3.51
+57.89%
-8.33
Change In Other Working Capital
-0.07
+99.28%
-9.92
-1093.89%
1.00
—
Change In Other Current Liabilities
-1.45
-17.79%
-1.23
-151.08%
2.41
-43.41%
4.26
Investing Cash Flow
58.86
+621.73%
8.15
+107.78%
-104.85
-1538.52%
-6.40
Cash Flow From Continuing Investing Activities
58.86
+621.73%
8.15
+107.78%
-104.85
-1538.52%
-6.40
Net PPE Purchase And Sale
-0.01
+96.20%
-0.24
+96.48%
-6.73
-5.11%
-6.40
Purchase Of PPE
-0.01
+96.20%
-0.24
+96.48%
-6.73
-5.11%
-6.40
Capital Expenditure
-0.01
+96.20%
-0.24
+96.48%
-6.73
-5.11%
-6.40
Net Investment Purchase And Sale
58.87
+601.45%
8.39
+108.01%
-104.78
0.00
Purchase Of Investment
-107.00
+33.17%
-160.12
+18.65%
-196.83
0.00
Sale Of Investment
165.87
-1.57%
168.51
+83.07%
92.05
0.00
Net Business Purchase And Sale
—
0.00
-100.00%
6.66
0.00
Purchase Of Business
—
—
—
0.00
Financing Cash Flow
0.59
-99.00%
59.33
+900.61%
5.93
+3139.89%
0.18
Cash Flow From Continuing Financing Activities
0.59
-99.00%
59.33
+900.61%
5.93
+3139.89%
0.18
Net Common Stock Issuance
0.00
-100.00%
59.05
+864.49%
6.12
0.00
Proceeds From Stock Option Exercised
0.74
+42.31%
0.52
+106.35%
0.25
+37.70%
0.18
Net Other Financing Charges
-0.15
+38.33%
-0.24
+46.07%
-0.45
—
Changes In Cash
-4.05
-141.30%
9.81
+105.78%
-169.63
-77.53%
-95.55
Beginning Cash Position
20.95
+88.08%
11.14
-93.84%
180.76
-34.58%
276.32
End Cash Position
16.89
-19.34%
20.95
+88.08%
11.14
-93.84%
180.76
Free Cash Flow
-63.51
-9.67%
-57.91
+25.22%
-77.44
+19.11%
-95.73
Interest Paid Supplemental Data
0.09
+810.00%
0.01
+900.00%
0.00
—
Income Tax Paid Supplemental Data
1.38
+740.85%
0.16
+241.67%
0.05
+182.35%
0.02
Amortization Of Securities
-2.96
+51.55%
-6.11
-27.59%
-4.79
0.00
Common Stock Issuance
0.00
-100.00%
59.05
+864.49%
6.12
0.00
Earnings Losses From Equity Investments
—
—
—
0.00
Issuance Of Capital Stock
0.00
-100.00%
59.05
+864.49%
6.12
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Sale Of Business
—
0.00
-100.00%
6.66
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category